A systematic review on the molecular pathways of Ameloblastic carcinoma when compared to Ameloblastoma.

IF 3.9 3区医学 Q1 PATHOLOGY

Expert Review of Molecular Diagnostics Pub Date : 2025-07-01 Epub Date: 2025-04-28 DOI:10.1080/14737159.2025.2499180

Nikita Garg, Revathi Krishna, Aadithya B Urs, Priya Kumar, Jeyaseelan Augustine

{"title":"A systematic review on the molecular pathways of Ameloblastic carcinoma when compared to Ameloblastoma.","authors":"Nikita Garg, Revathi Krishna, Aadithya B Urs, Priya Kumar, Jeyaseelan Augustine","doi":"10.1080/14737159.2025.2499180","DOIUrl":null,"url":null,"abstract":"Background: Ameloblastic carcinoma (AC), malignancy originating from the odontogenic epithelium, shows histological overlap with ameloblastoma (AM). In order to unravel mechanisms driving AC, it is imperative to understand the molecular distinction between these two entities. This systematic review aims to highlight molecular and immunohistochemical markers involved in the pathogenesis of AC and to distinguish it from its histological mimic, AM.Research design and methods: Literature search across three databases including PubMed, Web of Sciences, and Scopus was carried out from year 1999 to 2023 for original human case control studies involving AM, AC, and controls as study groups. Various biological markers studied in the literature were grouped based on principal molecular pathways. Joanna Briggs Institute (JBI), a critical appraisal tool for case control studies, was used to assess the risk of bias (RoB).Results: Out of the 277 studies identified during the initial search, 28 studies were found eligible. These studies reported expression of various immunohistochemical (IHC), genetic and epigenetic markers in AC, AM, and controls through immunohistochemistry and gene sequencing.Conclusion: Stem cells, epigenetics, and growth factors define the pathways involved in pathogenesis of AC and may prove to be a potential therapeutic target in the future.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"395-407"},"PeriodicalIF":3.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737159.2025.2499180","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Ameloblastic carcinoma (AC), malignancy originating from the odontogenic epithelium, shows histological overlap with ameloblastoma (AM). In order to unravel mechanisms driving AC, it is imperative to understand the molecular distinction between these two entities. This systematic review aims to highlight molecular and immunohistochemical markers involved in the pathogenesis of AC and to distinguish it from its histological mimic, AM.

Research design and methods: Literature search across three databases including PubMed, Web of Sciences, and Scopus was carried out from year 1999 to 2023 for original human case control studies involving AM, AC, and controls as study groups. Various biological markers studied in the literature were grouped based on principal molecular pathways. Joanna Briggs Institute (JBI), a critical appraisal tool for case control studies, was used to assess the risk of bias (RoB).

Results: Out of the 277 studies identified during the initial search, 28 studies were found eligible. These studies reported expression of various immunohistochemical (IHC), genetic and epigenetic markers in AC, AM, and controls through immunohistochemistry and gene sequencing.

Conclusion: Stem cells, epigenetics, and growth factors define the pathways involved in pathogenesis of AC and may prove to be a potential therapeutic target in the future.

查看原文本刊更多论文

成釉细胞癌与成釉细胞瘤分子途径的系统综述。

背景：成釉细胞癌（AC）是一种起源于牙源性上皮的恶性肿瘤，在组织学上与成釉细胞瘤（AM）有重叠。为了揭示驱动AC的机制，有必要了解这两种实体之间的分子区别。本系统综述旨在强调参与AC发病机制的分子和免疫组织化学标志物，并将其与组织学类似物AM区分开来。研究设计和方法：从1999年到2023年，在PubMed、Web of Sciences和Scopus三个数据库中进行文献检索，以AM、AC和对照组为研究小组进行原始人类病例对照研究。文献中研究的各种生物标记物根据主要分子途径进行分组。乔安娜布里格斯研究所（JBI）是病例对照研究的关键评估工具，用于评估偏倚风险（RoB）。结果：在最初的检索过程中确定的277项研究中，有28项研究符合条件。这些研究通过免疫组织化学和基因测序报道了AC、AM和对照中各种免疫组织化学（IHC）、遗传和表观遗传标记的表达。结论：干细胞、表观遗传学和生长因子决定了AC的发病途径，并可能在未来被证明是潜在的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Molecular Diagnostics 医学-病理学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Expert Review of Molecular Diagnostics (ISSN 1473-7159) publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting. Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations featuring assessments of significant, recently published articles from specialists in molecular diagnostic therapy. Expert Review of Molecular Diagnostics provides the forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community.